Gallacher Capital Management LLC Increases Stock Holdings in Lantheus Holdings, Inc. $LNTH

Gallacher Capital Management LLC grew its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 228.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,388 shares of the medical equipment provider’s stock after purchasing an additional 9,317 shares during the period. Gallacher Capital Management LLC’s holdings in Lantheus were worth $687,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in LNTH. Stanley Laman Group Ltd. raised its holdings in Lantheus by 38.7% in the third quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after acquiring an additional 22,229 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Lantheus during the 3rd quarter worth approximately $2,184,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Lantheus in the 3rd quarter valued at approximately $3,866,000. Fox Run Management L.L.C. acquired a new stake in shares of Lantheus in the 2nd quarter valued at $654,000. Finally, Nordea Investment Management AB raised its holdings in shares of Lantheus by 1.6% in the 2nd quarter. Nordea Investment Management AB now owns 48,075 shares of the medical equipment provider’s stock valued at $3,913,000 after purchasing an additional 737 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on LNTH. Mizuho boosted their target price on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Truist Financial lifted their price target on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Finally, The Goldman Sachs Group set a $77.00 target price on Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Stock Performance

NASDAQ LNTH opened at $65.93 on Thursday. The company has a fifty day moving average of $65.35 and a two-hundred day moving average of $59.74. The company has a market capitalization of $4.37 billion, a PE ratio of 27.70 and a beta of -0.08. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.29. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.67 and a quick ratio of 2.49.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, meeting the consensus estimate of $1.27. The business had revenue of $384.01 million during the quarter, compared to the consensus estimate of $363.42 million. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The business’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.70 EPS. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.